Figure 3
Figure 3. Forest plot of subgroup analysis for achievement of RBC-TI for ≥ 26 weeks in patients randomized to lenalidomide (LEN) 10 mg or 5 mg (mITT population). Horizontal bars represent 95% CI. / *Based on central hematologic review. / †EPO level data were missing for 10 patients in the 5 mg group and 6 patients in the 10 mg group. / ‡Because of the small number of patients with del5q31 plus ≥ 2 additional abnormalities (n = 5), this group was combined with those with del5q31 plus 1 additional abnormality to allow comparison with the isolated del5q31 group. Among the 5 patients randomized to lenalidomide with del5q31 plus ≥ 2 additional abnormalities, 1 patient in the lenalidomide 5 mg group achieved RBC-TI for ≥ 26 weeks. / OR indicates odds ratio; RARS, RA with ringed sideroblasts; WPSS, World Health Organization classification-based Prognostic Scoring System; and ESA, erythropoiesis-stimulating agent.

Forest plot of subgroup analysis for achievement of RBC-TI for ≥ 26 weeks in patients randomized to lenalidomide (LEN) 10 mg or 5 mg (mITT population). Horizontal bars represent 95% CI.

*Based on central hematologic review.

†EPO level data were missing for 10 patients in the 5 mg group and 6 patients in the 10 mg group.

‡Because of the small number of patients with del5q31 plus ≥ 2 additional abnormalities (n = 5), this group was combined with those with del5q31 plus 1 additional abnormality to allow comparison with the isolated del5q31 group. Among the 5 patients randomized to lenalidomide with del5q31 plus ≥ 2 additional abnormalities, 1 patient in the lenalidomide 5 mg group achieved RBC-TI for ≥ 26 weeks.

OR indicates odds ratio; RARS, RA with ringed sideroblasts; WPSS, World Health Organization classification-based Prognostic Scoring System; and ESA, erythropoiesis-stimulating agent.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal